Sensus Healthcare (SRTS) Receives a Buy from Maxim Group

In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Sensus Healthcare (SRTSResearch Report), with a price target of $20.00. The company’s shares closed last Friday at $14.55, close to its 52-week high of $14.82.

According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 3.8% and a 36.3% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Guardion Health Sciences, Applied DNA Sciences, and Dermata Therapeutics.

Sensus Healthcare has an analyst consensus of Strong Buy, with a price target consensus of $16.88, representing a 34.2% upside. In a report released yesterday, Alliance Global Partners also maintained a Buy rating on the stock with a $17.50 price target.

See the top stocks recommended by analysts >>

Sensus Healthcare’s market cap is currently $242.7M and has a P/E ratio of 9.65.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SRTS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sensus Healthcare, Inc. engages in the design, manufacture, and marketing of proprietary medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions. Its main product is SRT-100, a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers and other skin conditions such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.

Read More on SRTS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More